Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Memphis
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Mean corpuscular hemoglobin
Study Overview
Brief Summary
The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months.
Despite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness.
Therefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •experience regular (2 or more days per week) bloating or constipation
- •able to fast a minimum of 12 hours prior to testing visit
Exclusion Criteria
- •pregnant, planning to become pregnant, or breastfeeding
- •sensitivity or allergic to any components of the study product (cascara sagrada bark powder, cape aloe leaves extract, senna leaf powder, frangula bark powder fennel seed powder, bentonite clay, burdock root powder, licorice root extract, slippery elm bark powder, Capiscum annuum L. Fruit powder, milk thistle seed powder, hydroxypropyl methylcellulose, cellulose, and silicon dioxide).
- •experienced a severe allergic reaction that resulted in emergency care
- •diagnosed with medical disorders linked to digestive/gut health such as celiac disease, crohn's disease, gastroesophageal reflux disease, heartburn, irritable bowel syndrome, ulcerative colitis, ulcers, etcetera.
- •experiencing regular diarrhea
- •active infection or illness
- •hypertensive
- •cardiovascular disease
- •breast, uterine, or ovarian cancer
- •uterine fibroids or endometriosis
- •taking medications or supplements that may alter gut health including but not limited to diuretics, laxatives, anti-diarrheal, anticholinergic agents, or antispasmodic agents.
- •previous adverse experience with laxatives
- •taking medications known to interact with the dietary supplement's ingredients including blood pressure medications, anticoagulants, antiplatelets, blood thinners, cholesterol-lowering medications, diuretics, water pills, estrogen based contraceptives, non-steroidal anti-inflammatory drugs, digoxin, corticosteroids, Monoamine oxidase inhibitors, insulin, medications processed in the liver, diclofenac, fluvastatin, glipizide, ibuprofen, piroxicam, phenytoin, phenobarbital, or secobarbital.
- •tobacco user
- •strenuous activity within 24 hours of testing visits
- •caffeine within 24 hours of testing visit
- •alcohol within 24 hours of testing visit
Arms & Interventions
Experimental Dietary Supplement
15 randomly assigned individuals will receive 2 capsules daily of the experimental dietary supplement for 2 weeks with assessments prior and after intervention.
Intervention: Dietary supplement for digestive health (Dietary Supplement)
Placebo Control
15 randomly assigned individuals will receive 2 capsules daily of the placebo for 2 weeks with assessments prior and after intervention.
Intervention: placebo capsule (Dietary Supplement)
Outcomes
Primary Outcomes
Mean corpuscular hemoglobin
Time Frame: 2 weeks of assigned intervention
Mean corpuscular hemoglobin as part of a complete blood count panel measured in picograms
Mean corpuscular hemoglobin concentration
Time Frame: 2 weeks of assigned intervention
Mean corpuscular hemoglobin concentration as part of a complete blood count panel measured in grams per deciliter
Red cell distribution width
Time Frame: 2 weeks of assigned intervention
Red cell distribution width as part of a complete blood count panel measured as a percentage
Platelets
Time Frame: 2 weeks of assigned intervention
Platelets as part of a complete blood count panel measured as a count per 1000 per microliter
Specific gravity
Time Frame: 2 weeks of assigned intervention
Specific gravity as measured as part of urinalysis (no units)
pH
Time Frame: 2 weeks of assigned intervention
pH as measured as part of urinalysis (no units)
Urine color
Time Frame: 2 weeks of assigned intervention
Urine color as reported as part of urinalysis (no units)
Urine Appearance
Time Frame: 2 weeks of assigned intervention
Urine Appearance as reported as part of urinalysis (no units)
White Blood Cell esterase
Time Frame: baseline
White blood cell esterase as measured as part of urinalysis, if present
White blood cell esterase
Time Frame: 2 weeks of assigned intervention
White blood cell esterase as measured as part of urinalysis, if present
Protein
Time Frame: 2 weeks of assigned intervention
Protein as measured as part of urinalysis, if present
Glucose
Time Frame: 2 weeks of assigned intervention
Glucose as measured as part of urinalysis, if present
Ketones
Time Frame: 2 weeks of assigned intervention
Ketones as measured as part of urinalysis, if present
Occult blood
Time Frame: 2 weeks of assigned intervention
Occult blood as measured as part of urinalysis, if present
Bilirubin
Time Frame: 2 weeks of assigned intervention
Bilirubin as measured as part of urinalysis, if present
Urobilinogen
Time Frame: 2 weeks of assigned intervention
Urobilinogen as measured as part of urinalysis in milligrams per deciliter
Microscopic examination
Time Frame: 2 weeks of assigned intervention
Microscopic examination as reported as part of urinalysis, if indicated
Total Cholesterol
Time Frame: 2 weeks of assigned intervention
Total Cholesterol as reported as part of lipid panel in milligrams per deciliter
Triglycerides
Time Frame: 2 weeks of assigned intervention
Triglycerides as reported as part of lipid panel in milligrams per deciliter
High-Density Lipoprotein Cholesterol
Time Frame: 2 weeks of assigned intervention
High-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Very Low-Density Lipoprotein Cholesterol
Time Frame: 2 weeks of assigned intervention
Very Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Low-Density Lipoprotein Cholesterol
Time Frame: 2 weeks of assigned intervention
Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Calcium
Time Frame: 2 weeks of assigned intervention
Calcium measured as part of metabolic panel in milligrams per deciliter
Carbon dioxide
Time Frame: 2 weeks of assigned intervention
Carbon dioxide measured as part of metabolic panel in millimoles per liter
Chloride
Time Frame: 2 weeks of assigned intervention
Chloride measured as part of metabolic panel in millimoles per liter.
Creatinine
Time Frame: 2 weeks of assigned intervention
Creatinine measured as part of metabolic panel in milligrams per deciliter
Estimated glomerular filtration rate
Time Frame: 2 weeks of assigned intervention
Estimated glomerular filtration rate as part of metabolic panel in milliliters per minute per 1.73
Blood Glucose
Time Frame: 2 weeks of assigned intervention
Glucose measured as part of metabolic panel in milligrams per deciliter
Potassium
Time Frame: 2 weeks of assigned intervention
Potassium measured as part of metabolic panel in millimoles per liter.
Sodium
Time Frame: 2 weeks of assigned intervention
Sodium measured as part of metabolic panel in millimoles per liter.
Total Globulin
Time Frame: 2 weeks of assigned intervention
Total Globulin measured as part of metabolic panel in grams per deciliter
Total Protein
Time Frame: 2 weeks of assigned intervention
Total Protein measured as part of metabolic panel in grams per deciliter
Albumin/globulin ratio
Time Frame: 2 weeks of assigned intervention
Albumin/globulin ratio measured as part of metabolic panel
Blood urea nitrogen/creatinine ratio
Time Frame: 2 weeks of assigned intervention
Blood urea nitrogen/creatinine ratio measured as part of metabolic panel
Hematocrit
Time Frame: 2 weeks of assigned intervention
Hematocrit as part of a complete blood count panel measured as percentage
Hemoglobin
Time Frame: 2 weeks of assigned intervention
Hemoglobin as part of a complete blood count panel measured in grams per deciliter
Mean corpuscular volume
Time Frame: 2 weeks of assigned intervention
Mean corpuscular volume as part of a complete blood count panel measured in femtoliters
Blood urea nitrogen
Time Frame: 2 weeks of assigned intervention
Blood urea nitrogen measured as part of metabolic panel in milligrams per deciliter
Alanine transaminase
Time Frame: 2 weeks of assigned intervention
Alanine transaminase measured as part of metabolic panel in international units per liter
Aspartate transferase
Time Frame: 2 weeks of assigned intervention
Aspartate transferase measured as part of metabolic panel in international units per liter
Albumin
Time Frame: 2 weeks of assigned intervention
Albumin measured as part of metabolic panel in grams per deciliter
Alkaline phosphatase
Time Frame: 2 weeks of assigned intervention
Alkaline phosphatase measured as part of metabolic panel in international units per liter
Total bilirubin
Time Frame: baseline
Total bilirubin measured as part of metabolic panel in milligrams per deciliter
Total Bilirubin
Time Frame: 2 weeks of assigned intervention
Total bilirubin measured as part of metabolic panel in milligrams per deciliter
Mood questionnaire
Time Frame: 2 weeks of assigned intervention
Visual analog scale used to assess mood (attentive, tired, alert, groggy, focused, sluggish, energetic, lethargic, fatigued, mental clarity, motivation, happiness, and feeling from 0 (None) to 10 (Extreme) as well as "Flushed out" from 0 (not at all) to 10 (completely empty)
36-item short form survey
Time Frame: 2 weeks of assigned intervention
36-item questionnaire that measures health-related quality of life with responses used to calculate scores on a scale of 0-100, where higher scores indicate better health.
Tolerability Questionnaire
Time Frame: 2 weeks of assigned treatment
18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)
Bristol Chart
Time Frame: 14 days of assigned treatment
Self-reported number and consistency of daily bowel movements
Weight
Time Frame: 2 weeks of assigned treatment
Body weight measured in kg
Skin age
Time Frame: 2 weeks of assigned treatment
a quantitative skin age based on skin parameters will be determined by the 3D P Plus system
Triglycerides
Time Frame: 2 weeks of assigned intervention
Triglycerides as reported as part of lipid panel in milligrams per deciliter
Alanine transaminase
Time Frame: 2 weeks of assigned intervention
Alanine transaminase measured as part of metabolic panel in international units per liter
Aspartate transferase
Time Frame: 2 weeks of assigned intervention
Aspartate transferase measured as part of metabolic panel in international units per liter
Albumin
Time Frame: 2 weeks of assigned intervention
Albumin measured as part of metabolic panel in grams per deciliter
Alkaline phosphatase
Time Frame: 2 weeks of assigned intervention
Alkaline phosphatase measured as part of metabolic panel in international units per liter
Total bilirubin
Time Frame: baseline
Total bilirubin measured as part of metabolic panel in milligrams per deciliter
Total Bilirubin
Time Frame: 2 weeks of assigned intervention
Total bilirubin measured as part of metabolic panel in milligrams per deciliter
Blood urea nitrogen
Time Frame: 2 weeks of assigned intervention
Blood urea nitrogen measured as part of metabolic panel in milligrams per deciliter
Calcium
Time Frame: 2 weeks of assigned intervention
Calcium measured as part of metabolic panel in milligrams per deciliter
Carbon dioxide
Time Frame: 2 weeks of assigned intervention
Carbon dioxide measured as part of metabolic panel in millimoles per liter
Chloride
Time Frame: 2 weeks of assigned intervention
Chloride measured as part of metabolic panel in millimoles per liter.
Creatinine
Time Frame: 2 weeks of assigned intervention
Creatinine measured as part of metabolic panel in milligrams per deciliter
Estimated glomerular filtration rate
Time Frame: 2 weeks of assigned intervention
Estimated glomerular filtration rate as part of metabolic panel in milliliters per minute per 1.73
Blood Glucose
Time Frame: 2 weeks of assigned intervention
Glucose measured as part of metabolic panel in milligrams per deciliter
Potassium
Time Frame: 2 weeks of assigned intervention
Potassium measured as part of metabolic panel in millimoles per liter.
Sodium
Time Frame: 2 weeks of assigned intervention
Sodium measured as part of metabolic panel in millimoles per liter.
Total Globulin
Time Frame: 2 weeks of assigned intervention
Total Globulin measured as part of metabolic panel in grams per deciliter
Total Protein
Time Frame: 2 weeks of assigned intervention
Total Protein measured as part of metabolic panel in grams per deciliter
Albumin/globulin ratio
Time Frame: 2 weeks of assigned intervention
Albumin/globulin ratio measured as part of metabolic panel
Blood urea nitrogen/creatinine ratio
Time Frame: 2 weeks of assigned intervention
Blood urea nitrogen/creatinine ratio measured as part of metabolic panel
Hematocrit
Time Frame: 2 weeks of assigned intervention
Hematocrit as part of a complete blood count panel measured as percentage
Hemoglobin
Time Frame: 2 weeks of assigned intervention
Hemoglobin as part of a complete blood count panel measured in grams per deciliter
Mean corpuscular volume
Time Frame: 2 weeks of assigned intervention
Mean corpuscular volume as part of a complete blood count panel measured in femtoliters
Mean corpuscular hemoglobin
Time Frame: 2 weeks of assigned intervention
Mean corpuscular hemoglobin as part of a complete blood count panel measured in picograms
Mean corpuscular hemoglobin concentration
Time Frame: 2 weeks of assigned intervention
Mean corpuscular hemoglobin concentration as part of a complete blood count panel measured in grams per deciliter
Red cell distribution width
Time Frame: 2 weeks of assigned intervention
Red cell distribution width as part of a complete blood count panel measured as a percentage
Platelets
Time Frame: 2 weeks of assigned intervention
Platelets as part of a complete blood count panel measured as a count per 1000 per microliter
Specific gravity
Time Frame: 2 weeks of assigned intervention
Specific gravity as measured as part of urinalysis (no units)
pH
Time Frame: 2 weeks of assigned intervention
pH as measured as part of urinalysis (no units)
Urine color
Time Frame: 2 weeks of assigned intervention
Urine color as reported as part of urinalysis (no units)
Urine Appearance
Time Frame: 2 weeks of assigned intervention
Urine Appearance as reported as part of urinalysis (no units)
White Blood Cell esterase
Time Frame: baseline
White blood cell esterase as measured as part of urinalysis, if present
White blood cell esterase
Time Frame: 2 weeks of assigned intervention
White blood cell esterase as measured as part of urinalysis, if present
Protein
Time Frame: 2 weeks of assigned intervention
Protein as measured as part of urinalysis, if present
Glucose
Time Frame: 2 weeks of assigned intervention
Glucose as measured as part of urinalysis, if present
Ketones
Time Frame: 2 weeks of assigned intervention
Ketones as measured as part of urinalysis, if present
Occult blood
Time Frame: 2 weeks of assigned intervention
Occult blood as measured as part of urinalysis, if present
Bilirubin
Time Frame: 2 weeks of assigned intervention
Bilirubin as measured as part of urinalysis, if present
Urobilinogen
Time Frame: 2 weeks of assigned intervention
Urobilinogen as measured as part of urinalysis in milligrams per deciliter
Microscopic examination
Time Frame: 2 weeks of assigned intervention
Microscopic examination as reported as part of urinalysis, if indicated
Total Cholesterol
Time Frame: 2 weeks of assigned intervention
Total Cholesterol as reported as part of lipid panel in milligrams per deciliter
Very Low-Density Lipoprotein Cholesterol
Time Frame: 2 weeks of assigned intervention
Very Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Low-Density Lipoprotein Cholesterol
Time Frame: 2 weeks of assigned intervention
Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
High-Density Lipoprotein Cholesterol
Time Frame: 2 weeks of assigned intervention
High-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Mood questionnaire
Time Frame: 2 weeks of assigned intervention
Visual analog scale used to assess mood (attentive, tired, alert, groggy, focused, sluggish, energetic, lethargic, fatigued, mental clarity, motivation, happiness, and feeling from 0 (None) to 10 (Extreme) as well as "Flushed out" from 0 (not at all) to 10 (completely empty)
36-item short form survey
Time Frame: 2 weeks of assigned intervention
36-item questionnaire that measures health-related quality of life with responses used to calculate scores on a scale of 0-100, where higher scores indicate better health.
Tolerability Questionnaire
Time Frame: 2 weeks of assigned treatment
18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)
Weight
Time Frame: 2 weeks of assigned treatment
Body weight measured in kg
Diastolic blood pressure
Time Frame: 2 weeks of assigned treatment
Diastolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury
Bristol Chart
Time Frame: 14 days of assigned treatment
Self-reported number and consistency of daily bowel movements
Skin age
Time Frame: 2 weeks of assigned treatment
a quantitative skin age based on skin parameters will be determined by the 3D P Plus system
Heart rate
Time Frame: baseline
Heart rate will be measured using an automated blood pressure machine in units beats per minute
Heart Rate
Time Frame: 2 weeks of assigned treatment
Hear rate will be measured using an automated blood pressure machine in units beats per minute
Systolic blood pressure
Time Frame: 2 weeks of assigned treatment
Systolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury
Albumin
Time Frame: baseline
Albumin measured as part of metabolic panel in grams per deciliter
Alanine transaminase
Time Frame: baseline
Alanine transaminase measured as part of metabolic panel in international units per liter
Aspartate transferase
Time Frame: baseline
Aspartate transferase measured as part of metabolic panel in international units per liter
Alkaline phosphatase
Time Frame: baseline
Alkaline phosphatase measured as part of metabolic panel in international units per liter
Blood urea nitrogen
Time Frame: baseline
Blood urea nitrogen measured as part of metabolic panel in milligrams per deciliter
Calcium
Time Frame: baseline
Calcium measured as part of metabolic panel in milligrams per deciliter
Carbon dioxide
Time Frame: baseline
Carbon dioxide measured as part of metabolic panel in millimoles per liter
Chloride
Time Frame: baseline
Chloride measured as part of metabolic panel in millimoles per liter.
Creatinine
Time Frame: baseline
Creatinine measured as part of metabolic panel in milligrams per deciliter
Estimated glomerular filtration rate
Time Frame: baseline
Estimated glomerular filtration rate as part of metabolic panel in milliliters per minute per 1.73
Blood Glucose
Time Frame: baseline
Glucose measured as part of metabolic panel in milligrams per deciliter
Potassium
Time Frame: baseline
Potassium measured as part of metabolic panel in millimoles per liter.
Sodium
Time Frame: baseline
Sodium measured as part of metabolic panel in millimoles per liter.
Total Globulin
Time Frame: baseline
Total Globulin measured as part of metabolic panel in grams per deciliter
Total Protein
Time Frame: baseline
Total Protein measured as part of metabolic panel in grams per deciliter
Albumin/globulin ratio
Time Frame: baseline
Albumin/globulin ratio measured as part of metabolic panel
Blood urea nitrogen/creatinine ratio
Time Frame: baseline
Blood urea nitrogen/creatinine ratio measured as part of metabolic panel
Hematocrit
Time Frame: baseline
Hematocrit as part of a complete blood count panel measured as percentage
Hemoglobin
Time Frame: baseline
Hemoglobin as part of a complete blood count panel measured in grams per deciliter
Mean corpuscular volume
Time Frame: baseline
Mean corpuscular volume as part of a complete blood count panel measured in femtoliters
Mean corpuscular hemoglobin
Time Frame: baseline
Mean corpuscular hemoglobin as part of a complete blood count panel measured in picograms
Mean corpuscular hemoglobin concentration
Time Frame: baseline
Mean corpuscular hemoglobin concentration as part of a complete blood count panel measured in grams per deciliter
Red cell distribution width
Time Frame: baseline
Red cell distribution width as part of a complete blood count panel measured as a percentage
Platelets
Time Frame: baseline
Platelets as part of a complete blood count panel measured as a count per 1000 per microliter
Specific gravity
Time Frame: baseline
Specific gravity as measured as part of urinalysis (no units)
pH
Time Frame: baseline
pH as measured as part of urinalysis (no units)
Urine color
Time Frame: baseline
Urine color as reported as part of urinalysis (no units)
Urine Appearance
Time Frame: baseline
Urine Appearance as reported as part of urinalysis (no units)
Protein
Time Frame: baseline
Protein as measured as part of urinalysis, if present
Glucose
Time Frame: baseline
Glucose as measured as part of urinalysis, if present
Ketones
Time Frame: baseline
Ketones as measured as part of urinalysis, if present
Occult blood
Time Frame: baseline
Occult blood as measured as part of urinalysis, if present
Bilirubin
Time Frame: baseline
Bilirubin as measured as part of urinalysis, if present
Urobilinogen
Time Frame: baseline
Urobilinogen as measured as part of urinalysis in milligrams per deciliter
Microscopic examination
Time Frame: baseline
Microscopic examination as reported as part of urinalysis, if indicated
Total Cholesterol
Time Frame: baseline
Total Cholesterol as reported as part of lipid panel in milligrams per deciliter
Triglycerides
Time Frame: baseline
Triglycerides as reported as part of lipid panel in milligrams per deciliter
High-Density Lipoprotein Cholesterol
Time Frame: baseline
High-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Very Low-Density Lipoprotein Cholesterol
Time Frame: baseline
Very Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Low-Density Lipoprotein Cholesterol
Time Frame: baseline
Low-Density Lipoprotein Cholesterol as reported as part of lipid panel in milligrams per deciliter
Mood questionnaire
Time Frame: baseline
Visual analog scale used to assess mood (attentive, tired, alert, groggy, focused, sluggish, energetic, lethargic, fatigued, mental clarity, motivation, happiness, and feeling from 0 (None) to 10 (Extreme) as well as "Flushed out" from 0 (not at all) to 10 (completely empty)
36-item short form survey
Time Frame: baseline
36-item questionnaire that measures health-related quality of life with responses used to calculate scores on a scale of 0-100, where higher scores indicate better health.
Tolerability Questionnaire
Time Frame: baseline
18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)
Tolerability Questionnaire
Time Frame: 1 day of assigned treatment
18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)
Tolerability Questionnaire
Time Frame: 3 days of assigned treatment
18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)
Tolerability Questionnaire
Time Frame: 1 week of assigned treatment
18 item questionnaire covering upper abdominal, lower abdominal, and other symptoms using a 0-9 scale (0-no problem at all to 9-the worst it has ever been)
Bristol Chart
Time Frame: 3 days before baseline
Self-reported number and consistency of daily bowel movements
Bristol Chart
Time Frame: 2 days before baseline
Self-reported number and consistency of daily bowel movements
Bristol Chart
Time Frame: 1 day before baseline
Self-reported number and consistency of daily bowel movements
Bristol Chart
Time Frame: 1 day of assigned treatment
Self-reported number and consistency of daily bowel movements
Bristol Chart
Time Frame: 2 days on assigned treatment
Self-reported number and consistency of daily bowel movements
Bristol Chart
Time Frame: 3 days of assigned treatment
Self-reported number and consistency of daily bowel movements
Bristol Chart
Time Frame: 7 days of assigned treatment
Self-reported number and consistency of daily bowel movements
Weight
Time Frame: baseline
Body weight measured in kg
Skin age
Time Frame: baseline
a quantitative skin age based on skin parameters will be determined by the 3D P Plus system
Diastolic blood pressure
Time Frame: baseline
Diastolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury
Systolic blood pressure
Time Frame: baseline
Systolic blood pressure will be measured using an automated blood pressure machine in units millimeters of mercury
Secondary Outcomes
- Daily food diary(1 day prior to 2 week visit)
- Daily food diary(3 days prior to baseline visit)
- Daily food diary(2 days prior to baseline visit)
- Daily food diary(1 day prior to baseline visit)
- Daily food diary(3 days prior to 2 week visit)
- Daily food diary(2 days prior to 2 week visit)
Investigators
Richard Bloomer
Dean of College of Health Sciences
University of Memphis